Informatie: Dit is niet de actueelste versie van het datamodel. Een versieoverzicht vindt u links onder Versies. De actueelste versie vindt u hier.
Informatie:
Fout:
ID
42024
Beschrijving
Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Trefwoorden
Versies (4)
- 06-07-15 06-07-15 -
- 06-08-15 06-08-15 -
- 15-03-21 15-03-21 - Dr. rer. medic Philipp Neuhaus
- 20-09-21 20-09-21 -
Geüploaded op
15 maart 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0 Legacy
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
Imatinib Mesylate
Similar models
Imatinib Mesylate
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Date of first dose
Item
Date of first dose of imatinib mesylate received:
date
C3173309 (UMLS CUI-1)
Date of last dose
Item
Date of last dose of imatinib mesylate received:
date
C1762893 (UMLS CUI-1)
HIGHEST DOSE
Item
Highest dose of imatinib mesylate received (in mg):
float
C1522410 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
CL Item
Primary resistance (1)
CL Item
Acquired resistance (2)
CL Item
Intolerance (3)
TOLERABLE DOSE
Item
Has the subject ever tolerated a dose of imatinib mesylate greater than or equal to 600mg?
boolean
C3658296 (UMLS CUI-1)
C0178602 (UMLS CUI-2)
C0178602 (UMLS CUI-2)
CL Item
Fluid retention (1)
CL Item
Gastrointestinal symptoms (2)
CL Item
Arthralgia/ Myalgia (3)
CL Item
Rash (4)
CL Item
Other (5)
Specification
Item
If other, please specify:
text
C2348235 (UMLS CUI-1)
Item Group
BEST HEMATOLOGIC RESPONSE TO IMATINIB MESYLATE
C0205488 (UMLS CUI-1)
C0871261 (UMLS CUI-2)
C0939537 (UMLS CUI-3)
C0871261 (UMLS CUI-2)
C0939537 (UMLS CUI-3)
Item
Best hematologic response to imatinib mesylate:
text
C0205488 (UMLS CUI-1)
C0871261 (UMLS CUI-2)
C0939537 (UMLS CUI-3)
C0871261 (UMLS CUI-2)
C0939537 (UMLS CUI-3)
CL Item
Complete hematologic response (CHR) (1)
CL Item
Return to chronic phase (RTC) (2)
CL Item
No evidence of Leukemia (NEL) (3)
CL Item
No response to imatinib mesylate (4)
HEMATOLOGIC PROGRESSION DATE
Item
Date of most recent hematologic progression while on imatinib mesylate:
date
C0011008 (UMLS CUI-1)
C0449258 (UMLS CUI-2)
C0205488 (UMLS CUI-3)
C0449258 (UMLS CUI-2)
C0205488 (UMLS CUI-3)
DOSE
Item
Imatinib mesylate dose at time of most recent hematologic progression (in mg):
float
C0450442 (UMLS CUI [1,1])
C0677800 (UMLS CUI [1,2])
C1521941 (UMLS CUI [1,3])
C1521801 (UMLS CUI [1,4])
C0178602 (UMLS CUI [1,5])
C0677800 (UMLS CUI [1,2])
C1521941 (UMLS CUI [1,3])
C1521801 (UMLS CUI [1,4])
C0178602 (UMLS CUI [1,5])
Item Group
BEST CYTOGENETIC RESPONSE TO IMATINIB MESYLATE
CL Item
Complete cytogenetic response (CCyR) (1)
CL Item
Partial cytogenetic response (PCyR) (2)
CL Item
Minor cytogenetic response (3)
CL Item
Minimal cytogenetic respose (4)
CL Item
No response to Imatinib mesylate (5)
DATE
Item
Date of most recent cytogenetic progression while on imatinib mesylate:
date
C0011008 (UMLS CUI-1)
DOSE
Item
Imatinib mesylate dose at time of most recent cytogenetic progression (in mg):
float
C0450442 (UMLS CUI [1,1])
C0677800 (UMLS CUI [1,2])
C1521941 (UMLS CUI [1,3])
C1521801 (UMLS CUI [1,4])
C0178602 (UMLS CUI [1,5])
C0677800 (UMLS CUI [1,2])
C1521941 (UMLS CUI [1,3])
C1521801 (UMLS CUI [1,4])
C0178602 (UMLS CUI [1,5])